0000000000300046

AUTHOR

Esma R. Isenovic

showing 9 related works from this author

Peroxisome Proliferator-Activated Receptors and Atherosclerosis

2011

The peroxisome proliferator-activated receptors (PPARs) represent the family of 3 nuclear receptor isoforms-PPARα, -γ, and -δ/β, which are encoded by different genes. As lipid sensors, they are primarily involved in regulation of lipid metabolism and subsequently in inflammation and atherosclerosis. Atherosclerosis considers accumulation of the cells and extracellular matrix in the vessel wall leading to the formation of atherosclerotic plaque, atherothrombosis, and other vascular complications. Besides existence of natural ligands for PPARs, their more potent synthetic ligands are fibrates and thiazolidindiones. Future investigations should now focus on the mechanisms of PPARs activation, …

peroxisome proliferator-activated receptors gammaPeroxisome proliferator-activated receptor gammamedicine.medical_specialtyPeroxisome Proliferator-Activated Receptorsperoxisome proliferator-activated receptors alphaInflammationatherosclerotic plaque030204 cardiovascular system & hematology03 medical and health sciencesatherosclerosi0302 clinical medicineInternal medicineHumansMedicineReceptorHypolipidemic Agents030304 developmental biology0303 health sciencesbusiness.industryFibric Acidsperoxisome proliferator-activated receptors γLipid metabolismPeroxisomeAtherosclerosisLipid Metabolismperoxisome proliferator-activated receptors α3. Good healthEndocrinologyNuclear receptorCancer researchlipids (amino acids peptides and proteins)Peroxisome proliferator-activated receptor alphaatherosclerosismedicine.symptomSignal transductionCardiology and Cardiovascular MedicinebusinessSignal TransductionAngiology
researchProduct

Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome

2011

The metabolic syndrome (MetS) is common, and its associated risk burdens of diabetes and cardiovascular disease (CVD) are a major public health problem. The hypothesis that main constituent parameters of the MetS share common pathophysiologic mechanisms provides a conceptual framework for the future research. Exercise and weight loss can prevent insulin resistance and reduce the risk of diseases associated with the MetS. Interrupting intracellular and extracellular reactive oxygen species (ROS) overproduction could also contribute to normalizing the activation of metabolic pathways leading to the onset of diabetes, endothelial dysfunction, and cardiovascular (CV) complications. On the other…

medicine.medical_specialtyAntioxidantmedicine.medical_treatmentHyperlipidemiasDiseaseBioinformaticsmetabolic syndromeAntioxidants03 medical and health sciences0302 clinical medicineInsulin resistancecardiovascular diseaseWeight lossinsulin resistanceDiabetes mellitusInternal medicineDrug Discoverymedicineoxidative stressHumansObesityEndothelial dysfunctionantioxidants cardiovascular disease insulin resistance metabolic syndrome oxidative stress reactive oxygen species.Dyslipidemias030304 developmental biologyreactive oxygen speciesInflammationMetabolic SyndromePharmacology0303 health sciencesbusiness.industryThrombosismedicine.disease3. Good healthFatty LiverClinical trialOxidative StressantioxidantsEndocrinologyObesity Abdominal030220 oncology & carcinogenesisHypertensionInsulin ResistanceMetabolic syndromemedicine.symptombusinessSignal TransductionCurrent Pharmaceutical Design
researchProduct

Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches

2013

Small, dense low density lipoprotein (sdLDL) represents an emerging cardiovascular risk factor, since these particles can be associated with cardiovascular disease (CVD) independently of established risk factors, including plasma lipids. Obese subjects frequently have atherogenic dyslipidaemia, including elevated sdLDL levels, in addition to elevated triglycerides (TG), very low density lipoprotein (VLDL) and apolipoprotein-B, as well as decreased high density lipoprotein cholesterol (HDL-C) levels. Obesity-related co-morbidities, such as metabolic syndrome (MetS) are also characterized by dyslipidaemia. Therefore, agents that favourably modulate LDL subclasses may be of clinical value in t…

obesitymedicine.medical_specialtyVery low-density lipoproteinLipoproteinslipid-lowering drugsanti-obesity drugslcsh:TX341-641030209 endocrinology & metabolismReview030204 cardiovascular system & hematologyOverweight03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHigh-density lipoproteinInternal medicineHumansMedicineRisk factorDyslipidemiasMetabolic Syndromeobesity treatmentNutrition and Dieteticssmall dense low density lipoproteinbusiness.industryCholesterollipoproteinmedicine.disease3. Good healthEndocrinologychemistryCardiovascular DiseasesLow-density lipoproteinlipids (amino acids peptides and proteins)Metabolic syndromemedicine.symptombusinesslcsh:Nutrition. Foods and food supplyanti-obesity drugFood ScienceLipoproteinNutrients
researchProduct

High-Sensitivity C-Reactive Protein and Statin Initiation

2014

The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.

medicine.medical_specialtyStatinmedicine.drug_classInflammationBioinformaticsMultiple risk factorsRisk AssessmentPredictive Value of TestsRisk FactorsmedicineHumanscardiovascular diseasesDyslipidemiasInflammationbiologybusiness.industryPublic healthC-reactive protein3. Good healthCirculating biomarkersC-Reactive ProteinTreatment OutcomeCardiovascular DiseasesPractice Guidelines as TopicPhysical therapybiology.proteinBiomarker (medicine)Statin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation Mediatorsmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersAngiology
researchProduct

Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study

2014

Abstract Context: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. Objective: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). Design and Setting: A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical Biochemistry030209 endocrinology & metabolismContext (language use)Pilot ProjectsType 2 diabetes030204 cardiovascular system & hematologymedicine.disease_causeBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucagon-Like Peptide 1Internal medicineDiabetes mellitusMedicineHumansHypoglycemic AgentsProspective StudiesAgedbusiness.industryLiraglutideBiochemistry (medical)Liraglutide Heme oxygenase Lipid peroxidation Ghrelin Type-2 diabetesOriginal ArticlesLiraglutideMiddle Agedmedicine.diseaseGhrelinMetformin3. Good healthMetforminOxidative StressEndocrinologychemistryDiabetes Mellitus Type 2GhrelinDrug Therapy CombinationFemaleGlycated hemoglobinbusinessOxidative stressHeme Oxygenase-1medicine.drug
researchProduct

A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin

2013

Ghrelin is a peptide hormone produced mainly in the stomach that has widespread tissue distribution and diverse hormonal, metabolic and cardiovascular activities. The circulating ghrelin concentration increases during fasting and decreases after food intake. Ghrelin secretion may thus be initiated by food intake and is possibly controlled by nutritional factors. Lean subjects have increased levels of circulating ghrelin compared with obese subjects. Recent reports show that low plasma ghrelin is associated with elevated fasting insulin levels, insulin resistance and type 2 diabetes mellitus. Factors involved in the regulation of ghrelin secretion have not yet been defined; however, it is as…

medicine.medical_specialtyCardiotonic AgentsHyperlipidemias030209 endocrinology & metabolismPeptide hormoneBiologyCardiovascular System03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusInsulin SecretionDrug DiscoverymedicineAnimalsHumansHypoglycemic AgentsInsulinAntiatherogenic agentHypolipidemic Agents030304 developmental biology2. Zero hungerPharmacology0303 health sciencesEvidence-Based Medicinedigestive oral and skin physiologyType 2 Diabetes MellitusLipid Metabolismmedicine.diseaseGhrelin3. Good healthEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesGastric MucosaHyperglycemiaGhrelinhormones hormone substitutes and hormone antagonistsGhrelin secretionHormoneCurrent Pharmaceutical Design
researchProduct

Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome

2014

In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). W…

Riskmedicine.medical_specialtyOrganic Cation Transport ProteinsOrganic anion transporter 1Uric acid pre-hypertension metabolic sindrome cardiovascular metabolismGlucose Transport Proteins FacilitativeOrganic Anion TransportersHyperuricemia030204 cardiovascular system & hematologymetabolic syndromePrehypertensionPrehypertension03 medical and health scienceschemistry.chemical_compound0302 clinical medicineuric acidInternal medicinemedicineAnimalsHumanspre-hypertensionHyperuricemiaMetabolic SyndromePharmacologyOrganic cation transport proteinsbiologybusiness.industryMedicine (all)Glucose transporterCardiovascular riskmedicine.diseaseUric AcidMetabolic pathwayMetabolismEndocrinologychemistrybiology.proteinUric acidMetabolic syndromeCardiology and Cardiovascular MedicinebusinessPre-hypertensionmetabolism030217 neurology & neurosurgeryCurrent Vascular Pharmacology
researchProduct

Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome

2014

Resistin is an adipocyte- and monocyte-derived cytokine which has been implicated in the modulation of insulin action, energy, glucose and lipid homeostasis. Resistin has been associated with insulin resistance and many of its known complications. As a molecular link between metabolic signals, inflammation, and vascular dysfunction, resistin can be proposed as playing a significant role in the heightened inflammatory state induced by metabolic stress linked to excessive caloric intake, thus contributing to the risk for metabolic syndrome (MetS), type 2 diabetes (T2DM), and cardiovascular diseases (CVD). In this review, we highlighted the role of resistin, as an inflammatory cytokine, in the…

medicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentInflammationType 2 diabetesModels BiologicalType 2 diabetemetabolic syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceAdipocyteInternal medicineDiabetes mellitusDrug DiscoverymedicineHumansResistin030304 developmental biologyMetabolic SyndromePharmacology0303 health sciencesbusiness.industryDrug Discovery3003 Pharmaceutical ScienceMedicine (all)Insulinnutritional and metabolic diseasesCardiovascular diseasemedicine.disease3. Good healthcardiovascular diseasesEndocrinologyDiabetes Mellitus Type 2chemistryCardiovascular Diseases030220 oncology & carcinogenesisImmunologyResistintype 2 diabetesInflammation MediatorsMetabolic syndromemedicine.symptombusinesshormones hormone substitutes and hormone antagonists
researchProduct

Anesthetics and Cerebral Protection in Patients Undergoing Carotid Endarterectomy

2015

EREBRAL ISCHEMIA/HYPOXIA may occur in a vari-ety of perioperative circumstances. The main pathophy-siologic aspects involved in cerebral ischemia/reperfusion arecaused by adenosine triphosphate (ATP) consumption, theexcitotoxic actions of glutamate, changes in ionic homeostasis,and formation of free radicals (Fig 1). Outcomes from suchevents range from subclinical neurocognitive deficits to cata-strophic neurologic morbidity or death.

medicine.medical_specialtymedicine.medical_treatmentIschemiaCarotid endarterectomyAnesthesia GeneralNeuroprotectionSevofluraneBrain Ischemia03 medical and health sciences0302 clinical medicine030202 anesthesiologyInternal medicinemedicineAnimalsHumansIschemic PreconditioningSubclinical infectionEndarterectomy Carotidbusiness.industryGlutamate receptorPerioperativeHypoxia (medical)medicine.disease3. Good healthNeuroprotective AgentsAnesthesiology and Pain MedicineAnesthesiaAnesthetics InhalationCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgerymedicine.drugJournal of Cardiothoracic and Vascular Anesthesia
researchProduct